EA202092109A1 - КРИСТАЛЛИЧЕСКИЕ ФОРМЫ СТИМУЛЯТОРА sGC - Google Patents

КРИСТАЛЛИЧЕСКИЕ ФОРМЫ СТИМУЛЯТОРА sGC

Info

Publication number
EA202092109A1
EA202092109A1 EA202092109A EA202092109A EA202092109A1 EA 202092109 A1 EA202092109 A1 EA 202092109A1 EA 202092109 A EA202092109 A EA 202092109A EA 202092109 A EA202092109 A EA 202092109A EA 202092109 A1 EA202092109 A1 EA 202092109A1
Authority
EA
Eurasian Patent Office
Prior art keywords
crystalline forms
sgc stimulator
present
sgc
fluorobenzyl
Prior art date
Application number
EA202092109A
Other languages
English (en)
Russian (ru)
Inventor
Кваме В. Нти-Аддае
Лина Кумари Прасад
Томас Сторц
Original Assignee
Сайклерион Терапьютикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=65818696&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA202092109(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Сайклерион Терапьютикс, Инк. filed Critical Сайклерион Терапьютикс, Инк.
Publication of EA202092109A1 publication Critical patent/EA202092109A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
EA202092109A 2018-03-07 2019-03-07 КРИСТАЛЛИЧЕСКИЕ ФОРМЫ СТИМУЛЯТОРА sGC EA202092109A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862639846P 2018-03-07 2018-03-07
PCT/US2019/021080 WO2019173551A1 (en) 2018-03-07 2019-03-07 Crystalline forms of an sgc stimulator

Publications (1)

Publication Number Publication Date
EA202092109A1 true EA202092109A1 (ru) 2021-03-04

Family

ID=65818696

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202092109A EA202092109A1 (ru) 2018-03-07 2019-03-07 КРИСТАЛЛИЧЕСКИЕ ФОРМЫ СТИМУЛЯТОРА sGC

Country Status (21)

Country Link
US (3) US11466015B2 (https=)
EP (1) EP3762389B1 (https=)
JP (1) JP7423539B2 (https=)
KR (1) KR102782810B1 (https=)
CN (1) CN111836812A (https=)
AU (1) AU2019231724B2 (https=)
BR (1) BR112020018212A2 (https=)
CA (1) CA3092683A1 (https=)
CL (5) CL2020002284A1 (https=)
CO (1) CO2020012493A2 (https=)
CR (1) CR20200458A (https=)
EA (1) EA202092109A1 (https=)
ES (1) ES2980256T3 (https=)
IL (1) IL276853B1 (https=)
MA (1) MA54638A (https=)
MX (5) MX2023004858A (https=)
PE (1) PE20210124A1 (https=)
PH (1) PH12020551394A1 (https=)
SG (1) SG11202008641WA (https=)
TW (1) TWI823903B (https=)
WO (1) WO2019173551A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019231724B2 (en) 2018-03-07 2024-06-27 Tisento Therapeutics Inc. Crystalline forms of an sGC stimulator
KR20210031931A (ko) * 2018-07-11 2021-03-23 사이클리온 테라퓨틱스, 인크. 미토콘드리아 장애의 치료를 위한 sGC 자극제의 용도
US20230130739A1 (en) * 2020-03-26 2023-04-27 Cyclerion Therapeutics, Inc. DEUTERATED sGC STIMULATORS
EP4640676A1 (en) * 2022-12-21 2025-10-29 Sunshine Lake Pharma Co., Ltd. Crystal form of fluorine-substituted indazole compound and use thereof
AU2023412238A1 (en) * 2022-12-21 2025-07-03 Sunshine Lake Pharma Co., Ltd. Crystal form of fluorine-substituted indazole compound and use thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2928079B2 (ja) 1994-02-14 1999-07-28 永信薬品工業股▲ふん▼有限公司 １−（置換ベンジル）−３−（置換アリール）縮合ピラゾール類、その製造法及びその用途
DE19744026A1 (de) 1997-10-06 1999-04-08 Hoechst Marion Roussel De Gmbh Pyrazol-Derivate, ihre Herstellung und ihre Verwendung in Arzneimitteln
CN1332943C (zh) 1998-07-08 2007-08-22 萨诺费－阿文蒂斯德国有限公司 硫取代的磺酰基氨基羧酸n－芳基酰胺,其制备方法、用途以及含有该化合物的药物制剂
DE19830430A1 (de) 1998-07-08 2000-01-13 Hoechst Marion Roussel De Gmbh Schwefelsubstituierte Sulfonylamino-carbonsäure-N-arylamide, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
GB9824310D0 (en) 1998-11-05 1998-12-30 Univ London Activators of soluble guanylate cyclase
DE19942809A1 (de) 1999-09-08 2001-03-15 Bayer Ag Verfahren zur Herstellung substituierter Pyrimidinderivate
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE10216145A1 (de) 2002-04-12 2003-10-23 Bayer Ag Verwendung von Stimulatoren der löslichen Guanylatcyclase zur Behandlung von Glaukom
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
KR20100059952A (ko) 2007-09-06 2010-06-04 머크 샤프 앤드 돔 코포레이션 가용성 구아닐레이트 사이클라제 활성제
WO2009094242A1 (en) 2008-01-24 2009-07-30 Merck & Co., Inc. Angiotensin ii receptor antagonists
AU2009322836B2 (en) 2008-11-25 2013-04-04 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
CN102414194A (zh) 2009-02-26 2012-04-11 默沙东公司 可溶性鸟苷酸环化酶激活剂
US9284301B2 (en) 2010-03-25 2016-03-15 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
UA107112C2 (uk) 2010-05-27 2014-11-25 Мерк Шарп Енд Доме Корп. Активатори розчинної гуанілатциклази
AR088020A1 (es) 2010-06-30 2014-05-07 Ironwood Pharmaceuticals Inc Compuestos heterociclicos como estimuladores de sgc
EP2632551B1 (en) 2010-10-28 2016-07-06 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
EP2637659B1 (en) 2010-11-09 2016-05-18 Ironwood Pharmaceuticals, Inc. Sgc stimulators
CA2891976C (en) 2012-11-30 2020-07-21 Astellas Pharma Inc. Imidazopyridine compounds
US9776997B2 (en) 2013-06-04 2017-10-03 Bayer Pharma Aktiengesellschaft 3-aryl-substituted imidazo[1,2-A]pyridines and their use
CN104327107A (zh) 2013-10-17 2015-02-04 广东东阳光药业有限公司 一种氟喹诺酮类抗菌药物的制备方法
US9796733B2 (en) 2014-06-04 2017-10-24 Merck Sharp & Dohme Corp. Imidazo-pyrazine derivatives useful as soluble guanylate cyclase activators
EP3194386A2 (en) 2014-09-17 2017-07-26 Ironwood Pharmaceuticals, Inc. Sgc stimulators
CN107257796A (zh) * 2014-12-02 2017-10-17 拜耳医药股份有限公司 取代的吡唑并[1,5‑a]吡啶和咪唑并[1,2‑a]吡嗪及其用途
CR20220309A (es) * 2016-09-02 2022-09-16 Cyclerion Therapeutics Inc Estimuladores de sgc
AU2019231724B2 (en) 2018-03-07 2024-06-27 Tisento Therapeutics Inc. Crystalline forms of an sGC stimulator

Also Published As

Publication number Publication date
JP7423539B2 (ja) 2024-01-29
MX2023004856A (es) 2023-11-24
US20230095799A1 (en) 2023-03-30
MX2023004858A (es) 2023-11-24
US20250115611A1 (en) 2025-04-10
CR20200458A (es) 2020-11-09
AU2019231724B2 (en) 2024-06-27
CL2021003530A1 (es) 2022-08-19
KR20200128708A (ko) 2020-11-16
EP3762389B1 (en) 2024-02-28
IL276853B1 (en) 2026-01-01
MX2020009183A (es) 2020-10-08
CL2021003531A1 (es) 2022-08-19
CL2021003536A1 (es) 2022-08-19
MX2023004857A (es) 2023-11-24
CL2020002284A1 (es) 2020-11-27
TW201940487A (zh) 2019-10-16
CN111836812A (zh) 2020-10-27
WO2019173551A1 (en) 2019-09-12
PH12020551394A1 (en) 2021-11-22
MX2023004855A (es) 2023-11-24
CO2020012493A2 (es) 2020-10-30
CA3092683A1 (en) 2019-09-12
US12122782B2 (en) 2024-10-22
MA54638A (fr) 2021-11-10
TWI823903B (zh) 2023-12-01
BR112020018212A2 (pt) 2020-12-29
IL276853A (en) 2020-10-29
US11466015B2 (en) 2022-10-11
EP3762389A1 (en) 2021-01-13
PE20210124A1 (es) 2021-01-19
CL2021000301A1 (es) 2021-06-18
JP2021515015A (ja) 2021-06-17
KR102782810B1 (ko) 2025-03-14
US20210115050A1 (en) 2021-04-22
AU2019231724A1 (en) 2020-10-08
WO2019173551A8 (en) 2020-06-11
SG11202008641WA (en) 2020-10-29
ES2980256T3 (es) 2024-09-30

Similar Documents

Publication Publication Date Title
EA202092109A1 (ru) КРИСТАЛЛИЧЕСКИЕ ФОРМЫ СТИМУЛЯТОРА sGC
EA202090659A1 (ru) СОСТАВЫ, СОДЕРЖАЩИЕ 6-(2-ГИДРОКСИ-2-МЕТИЛПРОПОКСИ)-4-(6-(6-((6-МЕТОКСИПИРИДИН-3-ИЛ)МЕТИЛ)-3,6-ДИАЗАБИЦИКЛО[3.1.1]ГЕПТАН-3-ИЛ)ПИРИДИН-3-ИЛ)ПИРАЗОЛО[1,5-a]ПИРИДИН-3-КАРБОНИТРИЛ
MX2020008237A (es) Inhibidores de 2,3,4,5-tetrahidro-1h-pirido[4,3-b]indol de cgas para tratar enfermedades autoinflamatorias.
EA201791727A1 (ru) 7-бензил-4-(2-метилбензил)-2,4,6,7,8,9-гексагидроимидазо[1,2-а]пиридо[3,4-е]пиримидин-5(1н)-он, его аналоги и соли и способы их применения в терапии
PH12016502168B1 (en) Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
EA200500169A1 (ru) Замещенные производные 1,3-дифенилпроп-2-ен-1-она, получение и применение
PH12018500957A1 (en) Imidazo[4,5-c] quinolin -2-one compounds and their use in treating cancer
UA107952C2 (uk) ПОХІДНІ ІМІДАЗО[1,2-a]ПІРАЗИНУ І ЇХ ЗАСТОСУВАННЯ ДЛЯ ПРОФІЛАКТИКИ АБО ЛІКУВАННЯ НЕВРОЛОГІЧНИХ, ПСИХІАТРИЧНИХ І МЕТАБОЛІЧНИХ РОЗЛАДІВ І ЗАХВОРЮВАНЬ
EA202190323A1 (ru) ИМИДАЗО[1,2-b]ПИРИДАЗИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ Trk
EA200800992A1 (ru) 2-амино-7,8-дигидро-6н-пиридо[4,3-d]пиримидин-5-оны, способ их получения, способ терапии с их помощью, компонент композиции и композиция на их основе, 2,4-диоксопиперидиновые соединения для их получения
CR20210513A (es) Compuestos de haxahidro 1-h-pirazino[1,2-a]pirazina para el tratamiento de una enfermedad autoinmunitaria
MX2021012129A (es) Composiciones y método para utilizarlas para el tratamiento de enfermedades neurodegenerativas y mitocondriales.
NZ754944A (en) Imidazo [1,5-a] pyrazine derivatives as pi3kdelta inhibitors
NO20061137L (no) Cyklopropylderivater som NK3-reseptorantagonister
JOP20190209A1 (ar) مركبات إيميدازو [ 4، 5-c ] كينولين-2-أون ديوترومية واستخدامها في علاج السرطان
MX2020002630A (es) Derivados de imidazo[1,5-a]pirazina como inhibidores de fosfatidilinositol-4,5-bisfosfato 3-quinasadelta.
IS8377A (is) Arýlindenópyridín og arýlindenópyrimidín og notkun þeirra sem mótlyf A2A viðtaka adenósíns
EA200800223A1 (ru) ПРОИЗВОДНЫЕ ПИРИДО[2,3-d]ПИРИМИДИНА, ИХ ПОЛУЧЕНИЕ, ИХ ПРИМЕНЕНИЕ В ТЕРАПИИ
MXPA05012082A (es) Compuestos como antagonistas del receptor crf1.
MX347632B (es) Derivados de 6,7-dihidro-3h-oxazolo[3,4-a]pirazin-5,8-diona.
EA202092108A1 (ru) Способ получения стимуляторов растворимой гуанилатциклазы
MX2024003444A (es) Compuestos de pirazolo[3,4-b]piridina para el tratamiento de enfermedades autoinmunitarias.
SE0100297D0 (sv) New compounds
SE0303451D0 (sv) New compounds
EA202190165A1 (ru) 7-БЕНЗИЛ-4-(2-МЕТИЛБЕНЗИЛ)-2,4,6,7,8,9-ГЕКСАГИДРОИМИДАЗО[1,2-a]ПИРИДО[3,4-e]ПИРИМИДИН-5(1Н)-ОН, ЕГО АНАЛОГИ И СОЛИ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ В ТЕРАПИИ